Piper Sandler Maintains Overweight on Enfusion, Lowers Price Target to $12

Piper Sandler analyst Christopher Donat maintains Enfusion (NYSE:ENFN) with a Overweight and lowers the price target from $15 to $12.

Piper Sandler analyst Christopher Donat maintains Enfusion (NYSE:ENFN) with a Overweight and lowers the price target from $15 to $12.

Total
0
Shares
Related Posts